Oligodendroglial tumor chemotherapy using "decreased-dose- intensity" PCV: A Singapore experience

Neurology

Volumn 66, Issue 2, 2006, Pages 247-249

  Ty, A U ^a   See, S J ^a   Rao, J P ^b   Khoo, J B K ^c   Wong, M C ^a,c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b National Cancer Center   (Singapore)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; PROCARBAZINE; VINCRISTINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT;

ADULT; ANEMIA; ARTICLE; ASIAN; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; FEMALE; HUMAN; LEUKOPENIA; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; OLIGODENDROGLIOMA; PAIN; PRIORITY JOURNAL; SINGAPORE; VOMITING; BRAIN TUMOR; CLINICAL TRIAL; DOSE RESPONSE; ETHNOLOGY; SURVIVAL;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LOMUSTINE; MALE; OLIGODENDROGLIOMA; PROCARBAZINE; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 33644895167     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000194211.68164.a0     Document Type: Article

References (10)

1. Engelhard HH, Stelea A, Mundt A. Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment and prognosis. Surg Neurol 2003;60:443-456.
2. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994;12:2013-2021.
3. Diabira S, Rousselet M, Gamelin E, et al. PCV chemotherapy for oligodendroglioma: response analyzed on T2 weighted-MRI. J Neurooncol 2001;55:45-50.
4. Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of "standard" procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. Cancer 2004;101:2079-2085.
5. Van den Bent M, Kros JM, Heimans JJ, et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Neurology 1998;51:1140-1145.
6. Biemond-ter Stege EM, Kros JM, Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine and vincristine. Cancer 2005;103:802-804.
7. Schwartsmann G, Ratain MJ, Cragg GM, et al. Anti-cancer drug discovery and development throughout the world. J Clin Oncol 2002;20:47s-59s.
8. Wakabayashi T, Kajita Y, Mizuno M, et al. Efficacy of adjuvant therapy with procarbazine, MCNU, and vincristine for oligodendroglial tumors. Neurol Med Chir (Tokyo) 2001;42:115-119.
9. Higuchi Y, Iwadate Y, Yamaura A. Treatment of low-grade oligodendroglial tumors without radiotherapy. Neurology 2004;63:2384-2386.
10. Takakura K, Abe H, Tanaka R, et al. Effects of ACNU and radiotherapy on malignant glioma. J Neurosurg 1986;64:53-57.